|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-3.74/-3.29
|
企业价值
81.49M
|
资产负债 |
每股账面净值
2.84
|
现金流量 |
现金流量率
--
|
损益表 |
收益
0
|
每股收益
--
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/18 18:04 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatmentoptions. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD). |